Lou Gehrig’s Disease: Patients Take Research into Their Own Hands
(SANTA CRUZ, Calif.) -- Though his body betrays him, Eric Valor's mind is still strong. Diagnosed with Lou Gehrig's disease in 2004, the 43-year-old relies on machines to move, talk, eat and breathe. But that hasn't stopped him from running his own drug trial.
With help, Valor has been injecting sodium chlorite, a chemical used by water treatment plants, into his paralyzed body through a feeding tube. He's convinced it's the active ingredient in NP001, an experimental drug made by Neuraltus Pharmaceuticals Inc., and other patients are following his lead.
"My original plan was to keep it secret until I could report with confidence that it was safe and even marginally effective," said Valor, who started taking sodium chlorite in October 2011. "But the secret got out, so I made a website to try to capture data as best I could."
From a special bed in his Santa Cruz home, Valor uses only his eyes to control a ceiling-mounted computer -- an invention from his days as a computer specialist. He is able to track his disease progression and that of more than two dozen other patients taking sodium chlorite.
He hopes the makeshift drug will buy them all time until NP001 is approved by the U.S. Food and Drug Administration.
But experts say the DIY approach is dangerous.
"It's pretty frightening," said Dr. Jonathan Glass, neurologist and director of the Emory ALS Center in Atlanta. "I think it's a cry of desperation for these folks, using something not made to strict standards with no evidence it works."
But people with Lou Gehrig's disease, also known as ALS, are eager to find out whether sodium chlorite works quickly and on their own terms. Frustrated with the pace of clinical research, they've joined forces to tackle the best leads on short order, from off-label drugs to stem cell transplants, and now makeshift NP001. It's a far cry from a properly designed clinical trial, which has a control group to weed out the infamous placebo effect. Still, the DIY design puts patients back in control.
Research papers and patent filings suggest the vaguely-named NP001 could be sodium chlorite, but Neuraltus Pharmaceuticals Inc. has not publicly confirmed the drug's formula. Calls to the company were not immediately returned.
The results of a phase 2 clinical trial of NP001 are expected to come out later this year.
Copyright 2012 ABC News Radio